Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license agreement with Heidelberg University and Euratom, represented by the European Commission, Joint Research Centre. This pivotal agreement confers upon Fusion the exclusive worldwide rights to develop, manufacture, and commercialize compounds […]